Type 2 Diabetes Mellitus Worsens Arterial Stiffness in Hypertensive Patients Through Endothelial Dysfunction
Overview
Authors
Affiliations
Aims/hypothesis: Endothelium-derived factors are thought to be physiological modulators of large artery stiffness. The aim of the study was to investigate whether endothelial function could be a determinant of arterial stiffness in essential hypertensive patients, in relation with the concomitant presence of type 2 diabetes mellitus.
Methods: The study included 341 participants (84 hypertensive patients with and 175 without type 2 diabetes mellitus, 82 matched controls). Brachial artery endothelium-dependent flow-mediated dilation (FMD) was determined by high-resolution ultrasound and computerised edge detection system. Applanation tonometry was used to measure carotid-femoral pulse wave velocity (PWV).
Results: Hypertensive patients with diabetes had higher PWV (10.1 ± 2.3 m/s vs 8.6 ± 1.4 m/s, p < 0.001) and lower FMD (3.51 ± 2.07 vs 5.16 ± 2.96%, p < 0.001) than non-diabetic hypertensive patients, who showed impaired vascular function when compared with healthy participants (7.9 ± 1.6 m/s and 6.68 ± 3.67%). FMD was significantly and negatively correlated to PWV only in hypertensive diabetic patients (r = -0.456, p < 0.001), but not in hypertensive normoglycaemic patients (r = -0.088, p = 0.248) or in healthy participants (r = 0.008, p = 0.946). Multivariate analysis demonstrated that, in the diabetic group, FMD remained an independent predictor of PWV after adjustment for confounders (r(2) = 0.083, p = 0.003). Subgroup analysis performed in non-diabetic hypertensive patients revealed that neither obesity nor the metabolic syndrome affected the relationship between FMD and PWV.
Conclusions/interpretation: Endothelial dysfunction is a determinant of aortic stiffness in hypertensive diabetic patients but not in hypertensive patients without diabetes. These results suggest that type 2 diabetes mellitus on top of hypertension might worsen arterial compliance by endothelium-related mechanisms.
Liang X, Li D, Wang Z, Cheng Y, Mou K, Ye C Rev Cardiovasc Med. 2024; 25(9):339.
PMID: 39355589 PMC: 11440398. DOI: 10.31083/j.rcm2509339.
DOnofrio L, Amendolara R, Mignogna C, Leto G, Tartaglione L, Mazzaferro S Int J Mol Sci. 2023; 24(21).
PMID: 37958794 PMC: 10648693. DOI: 10.3390/ijms242115809.
Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease.
Dai Z, Chen J, Zou R, Liang X, Tang J, Yao C Front Immunol. 2023; 14:1213473.
PMID: 37809091 PMC: 10552262. DOI: 10.3389/fimmu.2023.1213473.
Chen S, Zhou K, Shang H, Du M, Wu L, Chen Y Front Endocrinol (Lausanne). 2023; 14:1216962.
PMID: 37780628 PMC: 10534066. DOI: 10.3389/fendo.2023.1216962.
Gram-Kampmann E, Olesen T, Hansen C, Hugger M, Jensen J, Handberg A Cardiovasc Diabetol. 2023; 22(1):212.
PMID: 37592243 PMC: 10436534. DOI: 10.1186/s12933-023-01956-8.